Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
    5.
    发明申请
    Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies 审中-公开
    基于免疫沉淀的测定用于预测β-淀粉样蛋白抗体的体内功效

    公开(公告)号:US20060240486A1

    公开(公告)日:2006-10-26

    申请号:US11304072

    申请日:2005-12-15

    IPC分类号: G01N33/567 G01N33/53

    摘要: In various aspects, the present invention provides methods and kits for predicting the therapeutic efficacy of an immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder by comparing the amount of Aβ monomer in an Aβ preparation which binds to the immunological reagent to an amount of one or more Aβ oligomers in the Aβ preparation which bind to the immunological reagent to determine a relative bound amount, and predicting the efficacy of the immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder based at least on the relative bound amount.

    摘要翻译: 在各个方面,本发明提供了用于通过比较Abeta制剂中Abeta单体的量来预测免疫试剂的治疗功效的方法和试剂盒,其鉴定具有治疗功效的免疫试剂或两者用于治疗淀粉样变性疾病 其结合免疫试剂至Aβ制备物中结合免疫试剂以确定相对结合量的一种或多种Abeta寡聚体的量,并预测免疫试剂的功效,鉴定具有治疗功效的免疫试剂,或 两者都用于至少基于相对结合量处理淀粉样变性疾病。

    Contextual fear conditioning for predicting immunotherapeutic efficacy
    10.
    发明申请
    Contextual fear conditioning for predicting immunotherapeutic efficacy 审中-公开
    用于预测免疫治疗功效的情境恐惧条件

    公开(公告)号:US20060153772A1

    公开(公告)日:2006-07-13

    申请号:US11305889

    申请日:2005-12-15

    申请人: Jack Jacobsen

    发明人: Jack Jacobsen

    IPC分类号: A61K49/00

    CPC分类号: A61K49/0008

    摘要: The invention provides methods for determining effective immunotherapeutic agents which may be used for the treatment of cognitive disorders.

    摘要翻译: 本发明提供了用于确定可用于治疗认知障碍的有效免疫治疗剂的方法。